Standardized Expression of 18F-NAV4694 and 11C-PiB b-amyloid PET results with the centiloid scale

Journal of Nuclear Medicine

Volumn 57, Issue 8, 2016, Pages 1233-1237

  Rowe, Christopher C ^a,b   Jones, Gareth ^a   Dore, Vincent ^a,c   Pejoska, Svetlana ^a   Margison, Laura ^a   Mulligan, Rachel S ^a   Gordon Chan, J ^a   Young, Kenneth ^a   Villemagne, Victor L ^a,b  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c CSIRO   (Australia)

Author keywords

Alzheimer's disease; Amyloid imaging; Betaamyloid; Centiloid; Standardization

Indexed keywords

2 [2 FLUORO 6 (METHYLAMINO) 3 PYRIDINYL] 1 BENZOFURAN 5 OL; PITTSBURGH COMPOUND B; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; BENZOFURAN DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; FLUORINATED HYDROCARBON; FLUORINE; FLUTAFURANOL; N-METHYL-2-(4'-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FRONTOTEMPORAL DEMENTIA; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE RECONSTRUCTION; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; STANDARD UPTAKE VALUE; THREE DIMENSIONAL IMAGING; VALIDATION PROCESS; BRAIN; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC IMAGING; FEMALE; MALE; METABOLISM; MOLECULAR IMAGING; PRACTICE GUIDELINE; PROCEDURES; PROTEIN ANALYSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARDS; TISSUE DISTRIBUTION;

ADULT; AMYLOID BETA-PEPTIDES; BENZOFURANS; BENZOTHIAZOLES; BRAIN; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; HYDROCARBONS, FLUORINATED; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES AS TOPIC; PROTEIN INTERACTION MAPPING; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84980494253     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.171595     Document Type: Article

References (26)

1. Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med. 2011;52:1733-1740.
2. Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11:669-678.
3. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129-135.
4. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718-1725.
5. 18F]flutemetamol data: comparison with standard of truth based on histopathology [abstract]. J Nucl Med. 2013;54(suppl 2):302.
6. 18F-florbetaben binding to beta-amyloid deposits in human brains. J Nucl Med. 2013;54: 723-731.
7. Landau SM, Breault C, Joshi AD, et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013;54:70-77.
8. Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959-1972.
9. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab. 2005;25:1528-1547.
10. Mourik JE, Lubberink M, Schuitemaker A, et al. Image-derived input functions for PET brain studies. Eur J Nucl Med Mol Imaging. 2009;36:463-471.
11. 11C]PIB studies in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2009;36: 1629-1638.
12. Su Y, Blazey TM, Owen CJ, et al. Quantitative amyloid imaging in autosomal dominant Alzheimer's disease: results from the DIAN study group. PLoS One. 2016;11:e0152082.
13. 11C-Pittsburgh compound-B PET images. J Nucl Med. 2014;55:1305-1307.
14. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67: 446-452.
15. Schmidt ME, Chiao P, Klein G, et al. The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement. 2015;11:1050-1068.
16. Villemagne VL, O'Keefe G, Mulligan RS, Rowe CC. Quantitative approaches to amyloid imaging. Methods Mol Biol. 2011;680:201-225.
17. Carrillo MC, Rowe CC, Szoeke C, et al. Research and standardization in Alzheimer's trials: reaching international consensus. Alzheimers Dement. 2013;9: 160-168.
18. Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11: 1-15.
19. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid beta deposition, neuro-degeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12:357-367.
20. Jack CR Jr, Wiste HJ, Lesnick TG, et al. Brain beta-amyloid load approaches a plateau. Neurology. 2013;80:890-896.
21. Juréus A, Swahn BM, Sandell J, et al. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J Neurochem. 2010;114: 784-794.
22. Sundgren-Andersson AK, Svensson SPS, Swahn BM, et al. AZD4694: fluo-rinated positron emission tomography (PET) radioligand for detection of beta-amyloid deposits [abstract]. Alzheimers Dement. 2009;5(4, suppl 1): P267-P268.
23. 18F-AZD4694, an amyloid-beta-specific PET radioligand. J Nucl Med. 2012;53:415-424.
24. 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia. J Nucl Med. 2013;54:880-886.
25. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319-329.
26. 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51:913-920.